Updated: January 19, 2026

Prevalite Shortage: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Current Availability Picture (Early 2026)
Shortage Timeline and Drivers
Clinical Implications for Prescribers
Therapeutic Alternatives by Indication
Key Drug Interaction Reminder
Tools to Help Your Patients Find Cholestyramine

A clinical briefing on the 2026 Prevalite (cholestyramine) shortage: availability data, prescribing implications, therapeutic alternatives, and tools for providers.

Cholestyramine — one of the oldest bile acid sequestrants still in clinical use, previously marketed under the brand name Prevalite — has been subject to intermittent supply disruptions that are affecting patient access across the United States. If you're fielding calls from patients unable to fill their prescriptions, or if your prescribing workflows are being disrupted by pharmacy stockouts, this update is for you.

This post covers the current availability picture, the factors driving the shortage, prescribing implications, alternative agents, and tools you can use to help your patients maintain continuity of care.

Current Availability Picture (Early 2026)

The brand-name Prevalite has been discontinued. All cholestyramine on the market is now generic. As of early 2026, availability is best characterized as follows:

Generic cholestyramine regular powder: Intermittently available; multiple manufacturers producing with inconsistent distribution.
Generic cholestyramine light powder: Similar availability; may be available when regular is not. Consider adding both formulations to your prescribing options.
Regional variation: Urban areas with multiple pharmacy options have better access. Rural areas and single-distributor regions experience more significant gaps.
FDA status: Cholestyramine has been listed on the FDA Drug Shortage Database intermittently. Verify current status at fda.gov before prescribing.

Shortage Timeline and Drivers

Supply issues with cholestyramine are not new, but they've become more persistent:

2022–2023: Sporadic stockouts at individual pharmacies; attributed to manufacturer production pauses and generic market consolidation.
2024: Intermittent FDA Drug Shortage Database listings as supplier reliability declined.
2025–2026: More widespread disruptions; multiple regions reporting consistent difficulty sourcing both regular and light formulations.

Key structural drivers include: raw material supply chain fragility, consolidation to a small number of generic manufacturers, growing off-label demand for bile acid diarrhea, and wholesale distribution allocation policies that create regional scarcity even when national supply exists.

Clinical Implications for Prescribers

The supply challenge has several practical implications for your practice:

Cholesterol management patients: Missing cholestyramine doses for a few weeks is unlikely to cause immediate harm, but LDL levels will rise. Monitor patients proactively if they report inability to fill prescriptions.
Bile acid diarrhea patients: These patients may experience significant symptom recurrence rapidly after stopping cholestyramine, leading to emergency visits or urgent calls. Prioritize these patients for early transition to alternatives if the shortage is prolonged in your area.
Biliary obstruction/pruritus patients: Itching can return quickly and severely impact quality of life. Consider early intervention.

Therapeutic Alternatives by Indication

For hypercholesterolemia:

Colesevelam (Welchol): Preferred alternative — same mechanism, tablet form, fewer drug interactions, better GI tolerability. Available generically.
Colestipol (Colestid): Same class; comparable efficacy; available as granules or tablets. Generic pricing comparable to cholestyramine.
Ezetimibe: Different mechanism (cholesterol absorption inhibitor); useful adjunct or alternative, particularly in statin-intolerant patients.
Statins: First-line for LDL lowering if not already in use and no contraindications. Revisit tolerability concerns if previously discontinued.

For bile acid diarrhea:

Colesevelam (Welchol): Most evidence-supported alternative for bile acid diarrhea. The 2023 SINBAD trial demonstrated colesevelam's superiority over placebo for inducing remission (64% vs. 16%).
Colestipol: Second-line option; comparable efficacy to cholestyramine in many patients.

Key Drug Interaction Reminder

When transitioning patients off cholestyramine, remind them — and document — the importance of re-timing any medications that were previously spaced around their cholestyramine dose. Cholestyramine significantly reduces absorption of warfarin, levothyroxine, digoxin, fat-soluble vitamins, mycophenolate, raloxifene, and many other agents. When cholestyramine is discontinued, these medications may have increased bioavailability; monitor appropriately (e.g., INR if on warfarin, TSH if on levothyroxine).

Tools to Help Your Patients Find Cholestyramine

medfinder is a service that contacts pharmacies near patients to find which ones have cholestyramine in stock. Patients provide their medication and zip code; medfinder calls pharmacies and texts the patient with results. If you have patients who are struggling to fill their prescriptions, refer them to

medfinder.com/providers to learn more about how medfinder can support your patients.

For a step-by-step guide to helping patients locate and manage access issues, see our

provider guide to helping patients find Prevalite in stock.

Frequently Asked Questions

Cholestyramine has been listed intermittently on the FDA Drug Shortage Database in recent years. As of early 2026, availability is best described as intermittent rather than a complete nationwide shortage. Always verify the current status at the FDA's drug shortage database at fda.gov before making prescribing decisions.

Colesevelam (Welchol) is the most commonly recommended alternative for bile acid diarrhea. It's a bile acid sequestrant with the same mechanism of action as cholestyramine but comes in tablet form and has fewer drug interactions. The 2023 SINBAD trial supported its efficacy for bile acid diarrhea remission. Colestipol (Colestid) is another option in the same class.

Yes. Cholestyramine reduces warfarin absorption, so patients on both medications typically have lower anticoagulation levels than they would on warfarin alone. When cholestyramine is discontinued, warfarin bioavailability may increase, leading to elevated INR. Monitor INR closely — typically within 1-2 weeks of stopping cholestyramine — and adjust warfarin dosing accordingly.

It depends on the patient's insurance plan. Colesevelam is often on a higher formulary tier than generic cholestyramine, so some plans may require prior authorization or step therapy documentation showing that cholestyramine was tried first. Document the shortage situation as the clinical rationale — most plans will process these requests efficiently when supply disruption is documented.

Refer patients to medfinder, which calls local pharmacies to check which ones have cholestyramine in stock — saving patients the time of calling pharmacies themselves. Also advise patients to ask their pharmacist about both regular and light formulations, try different pharmacy chains or independent pharmacies, and request a 90-day supply when stock is found.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards